These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 34508829)

  • 1. Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway.
    Kong D; Jiang Y; Miao X; Wu Z; Liu H; Gong W
    Biochim Biophys Acta Mol Basis Dis; 2021 Dec; 1867(12):166267. PubMed ID: 34508829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
    J Hepatol; 2022 Jan; 76(1):123-134. PubMed ID: 34464659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.
    Cho K; Ro SW; Lee HW; Moon H; Han S; Kim HR; Ahn SH; Park JY; Kim DY
    Hepatology; 2021 Nov; 74(5):2605-2621. PubMed ID: 34101869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
    Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
    Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of SSR2 Enhances Hepatocellular Carcinoma Cisplatin Sensitivity via the Hippo Pathway.
    Ye R; Yin L; Ge Y; Zhu X; Xiao Y; Fang C; Liu Q; Zhang H; Li H; Xie B
    Front Biosci (Landmark Ed); 2024 Aug; 29(8):299. PubMed ID: 39206890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of YAP/TAZ-Notch1-NICD axis by bromodomain and extraterminal protein inhibition impairs liver regeneration.
    Liu C; Cheng X; Chen J; Wang Y; Wu X; Tian R; Liu B; Ding X; Sun Q; Gong W
    Theranostics; 2019; 9(13):3840-3852. PubMed ID: 31281517
    [No Abstract]   [Full Text] [Related]  

  • 8. Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance.
    Chhonker SK; Rawat D; Koiri RK
    J Biochem Mol Toxicol; 2022 Aug; 36(8):e23100. PubMed ID: 35608386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
    Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
    J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma.
    Quan Y; Li Z; Zhu K; Liang J
    Lipids Health Dis; 2021 Jul; 20(1):74. PubMed ID: 34304741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP1 modulates hepatocellular carcinoma progression via the Hippo/TAZ axis.
    Liu D; Li Q; Zang Y; Li X; Li Z; Zhang P; Feng C; Yang P; Cui J; Sun Y; Wei T; Su P; Zhao X; Yang H; Ding Y
    Cell Death Dis; 2023 Apr; 14(4):264. PubMed ID: 37041150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
    Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
    Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
    Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
    Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
    Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
    Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.
    Saito Y; Yin D; Kubota N; Wang X; Filliol A; Remotti H; Nair A; Fazlollahi L; Hoshida Y; Tabas I; Wangensteen KJ; Schwabe RF
    Gastroenterology; 2023 Jun; 164(7):1279-1292. PubMed ID: 36894036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition.
    Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X
    Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
    Liang B; Wang H; Qiao Y; Wang X; Qian M; Song X; Zhou Y; Zhang Y; Shang R; Che L; Chen Y; Huang Z; Wu H; Monga SP; Zeng Y; Calvisi DF; Chen X; Chen X
    Hepatology; 2023 Jun; 77(6):1929-1942. PubMed ID: 35921500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
    Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
    Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.